Tiago Fauth
Stock Analyst at Wells Fargo
(1.38)
# 3,325
Out of 4,843 analysts
135
Total ratings
34.58%
Success rate
-10.39%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintains: Overweight | $8 → $7 | $2.28 | +207.02% | 2 | May 28, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $20 → $23 | $14.92 | +54.16% | 1 | May 28, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $68 → $74 | $48.52 | +52.51% | 2 | May 27, 2025 | |
| INZY Inozyme Pharma | Downgrades: Equal-Weight | $4 | $3.97 | +0.76% | 3 | May 16, 2025 | |
| VRNA Verona Pharma | Maintains: Overweight | $93 → $107 | $81.20 | +31.77% | 5 | Apr 30, 2025 | |
| UTHR United Therapeutics | Downgrades: Equal-Weight | $395 → $314 | $318.85 | -1.52% | 5 | Apr 25, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Overweight | $112 → $101 | $21.53 | +369.22% | 4 | Mar 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $275 → $287 | $304.56 | -5.77% | 5 | Mar 21, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Equal-Weight | $4 → $3 | $1.35 | +122.22% | 2 | Mar 4, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $28 → $26 | $14.15 | +83.75% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $6.07 | +180.07% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $107 | $69.73 | +53.45% | 3 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $88 | $34.03 | +158.60% | 7 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.15 | +116.87% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $22 | $6.01 | +266.06% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $46.68 | +60.67% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $1.70 | +3,547.06% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $162.73 | -45.31% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $13.92 | +266.38% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $58.07 | +106.65% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $14.85 | -73.06% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.65 | +428.30% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $5.68 | +357.75% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $2.02 | +1,286.14% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $16.93 | +378.44% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.41 | +1,855.99% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.21 | +1,057.02% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $0.49 | +6,903.09% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $3.07 | +4,785.99% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $43.04 | -32.62% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.27 | +923.62% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $1.72 | +655.81% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $0.80 | +149.22% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $572.79 | -40.64% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $288.18 | -10.13% | 1 | Apr 28, 2021 |
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $2.28
Upside: +207.02%
Liquidia
May 28, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $14.92
Upside: +54.16%
PTC Therapeutics
May 27, 2025
Maintains: Overweight
Price Target: $68 → $74
Current: $48.52
Upside: +52.51%
Inozyme Pharma
May 16, 2025
Downgrades: Equal-Weight
Price Target: $4
Current: $3.97
Upside: +0.76%
Verona Pharma
Apr 30, 2025
Maintains: Overweight
Price Target: $93 → $107
Current: $81.20
Upside: +31.77%
United Therapeutics
Apr 25, 2025
Downgrades: Equal-Weight
Price Target: $395 → $314
Current: $318.85
Upside: -1.52%
Tectonic Therapeutic
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $21.53
Upside: +369.22%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $275 → $287
Current: $304.56
Upside: -5.77%
Pliant Therapeutics
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.35
Upside: +122.22%
Keros Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $14.15
Upside: +83.75%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $6.07
Upside: +180.07%
Feb 19, 2025
Maintains: Overweight
Price Target: $85 → $107
Current: $69.73
Upside: +53.45%
Dec 20, 2024
Maintains: Overweight
Price Target: $75 → $88
Current: $34.03
Upside: +158.60%
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $4.15
Upside: +116.87%
Oct 16, 2024
Maintains: Overweight
Price Target: $11 → $22
Current: $6.01
Upside: +266.06%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $46.68
Upside: +60.67%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $1.70
Upside: +3,547.06%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $162.73
Upside: -45.31%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $13.92
Upside: +266.38%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $58.07
Upside: +106.65%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $14.85
Upside: -73.06%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.65
Upside: +428.30%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $5.68
Upside: +357.75%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $2.02
Upside: +1,286.14%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $16.93
Upside: +378.44%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.41
Upside: +1,855.99%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.21
Upside: +1,057.02%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $0.49
Upside: +6,903.09%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $3.07
Upside: +4,785.99%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $43.04
Upside: -32.62%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.27
Upside: +923.62%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $1.72
Upside: +655.81%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $0.80
Upside: +149.22%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $572.79
Upside: -40.64%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $288.18
Upside: -10.13%